liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Ludvigsson, Johnny
Alternative names
Publications (10 of 367) Show all publications
Long, A. E., Wilson, I. V., Becker, D. J., Libman, I. M., Arena, V. C., Wong, F. S., . . . Gillespie, K. M. (2018). Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia, 61(6), 1484-1490
Open this publication in new window or tab >>Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study
Show others...
2018 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 61, no 6, p. 1484-1490Article in journal (Refereed) Published
Abstract [en]

Aims/hypothesis Multiple islet autoimmunity increases risk of diabetes, but not all individuals positive for two or more islet autoantibodies progress to disease within a decade. Major islet autoantibodies recognise insulin (IAA), GAD (GADA), islet antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A). Here we describe the baseline characteristics of a unique cohort of slow progressors (n = 132) who were positive for multiple islet autoantibodies (IAA, GADA, IA-2A or ZnT8A) but did not progress to diabetes within 10 years. Methods Individuals were identified from five studies (BABYDIAB, Germany; Diabetes Autoimmunity Study in the Young [DAISY], USA; All Babies in Southeast Sweden [ABIS], Sweden; Barts Oxford Family Study [BOX], UK and the Pittsburgh Family Study, USA). Multiple islet autoantibody characteristics were determined using harmonised assays where possible. HLA class II risk was compared between slow progressors and rapid progressors (n = 348 diagnosed amp;lt; 5 years old from BOX) using the chi(2) test. Results In the first available samples with detectable multiple antibodies, the most frequent autoantibodies were GADA (92%), followed by ZnT8A (62%), IAA (59%) and IA-2A (41%). High risk HLA class II genotypes were less frequent in slow (28%) than rapid progressors (42%, p = 0.011), but only two slow progressors carried the protective HLA DQ6 allele. Conclusion No distinguishing characteristics of slow progressors at first detection of multiple antibodies have yet been identified. Continued investigation of these individuals may provide insights into slow progression that will inform future efforts to slow or prevent progression to clinical diabetes.

Place, publisher, year, edition, pages
SPRINGER, 2018
Keywords
HLA class II; Islet autoantibodies; Slow progression; Type 1 diabetes
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-147895 (URN)10.1007/s00125-018-4591-5 (DOI)000431650800024 ()29532109 (PubMedID)
Note

Funding Agencies|Diabetes UK-Fulbright Award; Diabetes UK Moffat Travelling Fellowship [13/0004636]; Diabetes UK [14/0004869]; JDRF [17-2013-529, 17-2013-535]; Deutsche Forschungsgemeinschaft (DFG) [ZI-310/14-1]; National Institutes of Health (NIH) [R01 DK32083, DK32493]; Vetenskapsradet; Novo Nordisk; Barndiabetesfonden; ALF grants; Region Ostergotland and Medical Research Council of southeast Sweden (Forskningsradet i sydostrasverige, FORSS) [12594]; NIH [R01 DK53456, DK56200, R01 DK24021]; NIDDK [PA-04-081]; Brehm Coalition by the University of Michigan Center for Computational Medicine and Biology Pilot Research Program NIH Grant [R01 DK46864]; General Clinical Research Center of the Childrens Hospital of Pittsburgh Grant [MO1 RR 00084]; Renziehausen fund

Available from: 2018-05-23 Created: 2018-05-23 Last updated: 2019-05-01
Knip, M., Akerblom, H. K., Al Taji, E., Becker, D., Bruining, J., Castano, L., . . . Wasikowa, R. (2018). Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes The TRIGR Randomized Clinical Trial. Journal of the American Medical Association (JAMA), 319(1), 38-48
Open this publication in new window or tab >>Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes The TRIGR Randomized Clinical Trial
Show others...
2018 (English)In: Journal of the American Medical Association (JAMA), ISSN 0098-7484, E-ISSN 1538-3598, Vol. 319, no 1, p. 38-48Article in journal (Refereed) Published
Abstract [en]

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the extensively hydrolyzed casein formula and 1078 to a conventional formula. The follow-up of the participants ended on February 28, 2017. INTERVENTIONS The participants received either a casein hydrolysate or a conventional adapted cows milk formula supplemented with 20% of the casein hydrolysate. The minimum duration of study formula exposure was 60 days by 6 to 8 months of age. MAIN OUTCOMES AND MEASURES Primary outcome was type 1 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS Among 2159 newborn infants (1021 female [47.3%]) who were randomized, 1744 (80.8%) completed the trial. The participants were observed for a median of 11.5 years (quartile [Q] 1-Q3, 10.2-12.8). The absolute risk of type 1 diabetes was 8.4% among those randomized to the casein hydrolysate (n = 91) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8%[95% CI, -1.6% to 3.2%]). The hazard ratio for type 1 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; P = .46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, -0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes.

Place, publisher, year, edition, pages
AMER MEDICAL ASSOC, 2018
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-144246 (URN)10.1001/jama.2017.19826 (DOI)000419116000014 ()29297078 (PubMedID)
Note

Funding Agencies|Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [HD040364, HD042444, HD051997]; Canadian Institutes of Health Research; Commission of the European Communities [QLK1-2002-00372]; European Foundation for the Study of Diabates/JDRF/Novo Nordisk; Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research) [250114]; Dutch Diabetes Research Foundation; Finnish Diabetes Research Foundation; JDRF

Available from: 2018-01-22 Created: 2018-01-22 Last updated: 2019-05-01
Simona Chisalita, I. & Ludvigsson, J. (2018). Insulin-Like Growth Factor-1 at Diagnosis and during Subsequent Years in Adolescents with Type 1 Diabetes. Journal of Diabetes Research, Article ID 8623560.
Open this publication in new window or tab >>Insulin-Like Growth Factor-1 at Diagnosis and during Subsequent Years in Adolescents with Type 1 Diabetes
2018 (English)In: Journal of Diabetes Research, ISSN 2314-6745, E-ISSN 2314-6753, article id 8623560Article in journal (Refereed) Published
Abstract [en]

Background. Type 1 diabetes (T1D) in adolescents is associated with alterations in the insulin-like factor system probably caused both by a deranged metabolism and insulinopenia in the portal vein.

Objective. To study how the circulating IGF-1 is affected at diagnosis and during subsequent years in adolescents with T1D.

Methods. Ten girls and ten boys with type 1 diabetes (T1D), aged 13.0 +/- 1.4 (mean +/- SD) years at diagnosis, took part in the study. Blood samples were drawn at diagnosis and after 3, 9, 18, and 48 months. HbA1c, total IGF-1, and C-peptide were measured.

Results. At diagnosis, the patients had high HbA1c, low IGF-1, and measurable C-peptide. After the start of insulin treatment, maximal improvement in glycemic control and IGF-1 occurred within 3 months and then both tended to deteriorate, that is, HbA1c to increase and IGF-1 to decrease. C-peptide decreased with time, and after 4 years, half of the patients were C-peptide negative. At diagnosis, C-peptide correlated positively to IGF-1 (r = 0 50; p amp;lt; 0 03). C-peptide correlated negatively with insulin dose (U/kg) after 18 and 48 months from diagnosis (r = -0 48; p amp;lt; 0 03 and r = -0 72; p amp;lt; 0 001, resp.).

Conclusions. In conclusion, our results show that in newly diagnosed adolescents with type 1 diabetes and deranged metabolism, the IGF-1 level is low and rapidly improves with insulin treatment but later tends to decrease concomitantly with declining endogenous insulin secretion.

Place, publisher, year, edition, pages
Hindawi Publishing Corporation, 2018
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-147455 (URN)10.1155/2018/8623560 (DOI)000428896300001 ()29744370 (PubMedID)
Note

Funding Agencies|Landstinget Ostergotland; Swedish Medical Research Council [04952]

Available from: 2018-05-16 Created: 2018-05-16 Last updated: 2019-02-28Bibliographically approved
Ludvigsson, J., Lefebvre, P. & Nerup, J. (2018). It is time to restore Rules for Authorship of scientific publications [Letter to the editor]. Pediatric Diabetes, 19(3), 586-586
Open this publication in new window or tab >>It is time to restore Rules for Authorship of scientific publications
2018 (English)In: Pediatric Diabetes, ISSN 1399-543X, E-ISSN 1399-5448, Vol. 19, no 3, p. 586-586Article in journal, Letter (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
WILEY, 2018
Keywords
authorship; fraud in research; research ethics
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-147920 (URN)10.1111/pedi.12572 (DOI)000430921600036 ()28994232 (PubMedID)2-s2.0-85045886791 (Scopus ID)
Available from: 2018-05-23 Created: 2018-05-23 Last updated: 2019-05-01Bibliographically approved
Ludvigsson, J. (2018). Nej – barn med typ 1-diabetes lever inte i ständig livsfara. Läkartidningen, 115
Open this publication in new window or tab >>Nej – barn med typ 1-diabetes lever inte i ständig livsfara
2018 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 115Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
Stockholm, Sweden: Läkartidningen Förlag AB, 2018
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-156937 (URN)30536231 (PubMedID)
Available from: 2019-05-15 Created: 2019-05-15 Last updated: 2019-06-14Bibliographically approved
Åkerman, L., Casas, R., Ludvigsson, J., Tavira Iglesias, B. & Skoglund, C. (2018). Serum miRNA levels are related to glucose homeostasis and islet autoantibodies in children with high risk for type 1 diabetes. PLoS ONE, 13(1), Article ID e0191067.
Open this publication in new window or tab >>Serum miRNA levels are related to glucose homeostasis and islet autoantibodies in children with high risk for type 1 diabetes
Show others...
2018 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 13, no 1, article id e0191067Article in journal (Refereed) Published
Abstract [en]

Micro RNAs (miRNAs) are promising disease biomarkers due to their high stability. Their expression in serum is altered in type 1 diabetes, but whether deviations exist in individuals with high risk for type 1 diabetes remains unexplored. We therefore assessed serum miRNAs in high-risk individuals (n = 21) positive for multiple islet autoantibodies, age-matched healthy children (n = 17) and recent-onset type 1 diabetes patients (n = 8), using Serum/Plasma Focus microRNA PCR Panels from Exiqon. The miRNA levels in the high-risk group were similar to healthy controls, and no specific miRNA profile was identified for the high-risk group. However, serum miRNAs appeared to reflect glycemic status and ongoing islet auto-immunity in high-risk individuals, since several miRNAs were associated to glucose homeostasis and autoantibody titers. High-risk individuals progressing to clinical disease after the sampling could not be clearly distinguished from non-progressors, while miRNA expression in the type 1 diabetes group deviated significantly from high-risk individuals and healthy controls, perhaps explained by major metabolic disturbances around the time of diagnosis.

Place, publisher, year, edition, pages
PUBLIC LIBRARY SCIENCE, 2018
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-145142 (URN)10.1371/journal.pone.0191067 (DOI)000422749500025 ()29346396 (PubMedID)
Note

Funding Agencies|Swedish Child Diabetes Foundation (Barndiabetesfonden); Swedish Research Council (Vetenskapsradet); Medical Research Council of Southeast Sweden (Forskningsradet i sydostra sverige, FORSS); Novo Nordisk Foundation; ALF/County Council of Ostergotland

Available from: 2018-02-13 Created: 2018-02-13 Last updated: 2019-05-21
Ludvigsson, J. (2018). Vi måste bli bättre på att diagnostisera typ 1-diabetes [Diagnostics of type 1 diabetes must be improved]. Läkartidningen, 115
Open this publication in new window or tab >>Vi måste bli bättre på att diagnostisera typ 1-diabetes [Diagnostics of type 1 diabetes must be improved]
2018 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 115Article in journal, Editorial material (Other academic) Published
Abstract [sv]

Incidence of type 1 diabetes in children and adolescents continues to increase but diagnosis is often delayed and keto-acidosis too common. More information is needed. General auto-antibody screening can be discussed.

Place, publisher, year, edition, pages
Stockholm, Sweden: Läkartidningen Förlag AB, 2018
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-156942 (URN)29381176 (PubMedID)
Available from: 2019-05-15 Created: 2019-05-15 Last updated: 2019-06-14Bibliographically approved
Ludvigsson, J. (2017). Etiken måste få väga tyngre än juridiken vid sena aborter [Ethics must be more important than the law in late abortions].. Läkartidningen, 114
Open this publication in new window or tab >>Etiken måste få väga tyngre än juridiken vid sena aborter [Ethics must be more important than the law in late abortions].
2017 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 114Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
Stockholm, Sweden: Läkartidningen Förlag AB, 2017
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-156938 (URN)28829485 (PubMedID)
Available from: 2019-05-15 Created: 2019-05-15 Last updated: 2019-06-14Bibliographically approved
Beam, C. A., MacCallum, C., Herold, K. C., Wherrett, D. K., Palmer, J. & Ludvigsson, J. (2017). GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia, 60(1), 43-49
Open this publication in new window or tab >>GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis
Show others...
2017 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 60, no 1, p. 43-49Article in journal (Refereed) Published
Abstract [en]

GAD is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. Randomised controlled clinical trials of a GAD + alum vaccine in human participants have so far given conflicting results. In this study, we sought to see whether a clearer answer to the question of whether GAD65 has an effect on C-peptide could be reached by combining individual-level data from the randomised controlled trials using Bayesian meta-analysis to estimate the probability of a positive biological effect (a reduction in C-peptide loss compared with placebo approximately 1 year after the GAD vaccine). We estimate that there is a 98% probability that 20 mu g GAD with alum administered twice yields a positive biological effect. The effect is probably a 15-20% reduction in the loss of C-peptide at approximately 1 year after treatment. This translates to an annual expected loss of between -0.250 and -0.235 pmol/ml in treated patients compared with an expected 2 h AUC loss of -0.294 pmol/ml at 1 year for untreated newly diagnosed patients. The biological effect of this vaccination should be developed further in order to reach clinically desirable reductions in insulin loss in patients recently diagnosed with type 1 diabetes.

Place, publisher, year, edition, pages
SPRINGER, 2017
Keywords
Bayes methods; Glutamic acid decarboxylase (GAD); Meta-analysis; Type 1 diabetes; Vaccine
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-133724 (URN)10.1007/s00125-016-4122-1 (DOI)000389634000007 ()27704166 (PubMedID)
Note

Funding Agencies|JDRF [1-INO-20140170-A-V]

Available from: 2017-01-11 Created: 2017-01-09 Last updated: 2018-05-02
Klingberg, S., Ludvigsson, J. & Brekke, H. K. (2017). Introduction of complementary foods in Sweden and impact of maternal education on feeding practices.. Public Health Nutrition, 20(6), 1054-1062
Open this publication in new window or tab >>Introduction of complementary foods in Sweden and impact of maternal education on feeding practices.
2017 (English)In: Public Health Nutrition, ISSN 1368-9800, E-ISSN 1475-2727, Vol. 20, no 6, p. 1054-1062Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To describe the introduction of complementary foods in a population-based cohort in relation to recommendations and explore the possible impact of maternal education on infant feeding practices.

DESIGN: Prospective data from the All Babies in Southeast Sweden (ABIS) cohort study were used. The ABIS study invited all infants born in south-east Sweden during October 1997-October 1999 (n 21 700) to participate. A questionnaire was completed for 16 022 infants. During the infants' first year parents continuously filed in a diary covering introduction of foods.

SETTING: Sweden.

SUBJECTS: Infants (n 9727) with completed food diaries.

RESULTS: Potatoes, vegetables, fruits/berries and porridge were the foods first introduced, with a median introduction between 19 and 22 weeks, followed by introduction of meat, cow's milk, follow-on formula and sour milk/yoghurt between 24 and 27 weeks. Early introduction of any food, before 16 weeks, occurred for 27 % of the infants and was more common in infants of mothers with low education. Overall, potatoes (14·7 %), vegetables (11·1 %), fruits/berries (8·5 %), porridge (7·4 %) and follow-on formula (2·7 %) were the foods most frequently introduced early. The majority of infants (≥70 %) were introduced to potatoes, vegetables, fruits/berries and porridge during concurrent breast-feeding, but introduction during concurrent breast-feeding was less common in infants of mothers with low education.

CONCLUSIONS: Most infants were introduced to complementary foods timely in relation to recommendations. Low maternal education was associated with earlier introduction of complementary foods and less introduction during concurrent breast-feeding. Still, the results indicated exposure to fewer foods at 12 months in infants of mothers with low education.

Place, publisher, year, edition, pages
John Wiley & Sons, 2017
National Category
Health Sciences
Identifiers
urn:nbn:se:liu:diva-134865 (URN)10.1017/S1368980016003104 (DOI)000399398300011 ()27917749 (PubMedID)
Note

Funding agencies: Swedish Child Diabetes Foundation (Barndiabetesfonden); Novo Nordisk Foundation; Research Council of Southeast Sweden (FORSS); Swedish Research Council [K2005-72X-11242-11A]; ALF/County Council of Ostergotland

Available from: 2017-02-27 Created: 2017-02-27 Last updated: 2018-05-02Bibliographically approved
Organisations

Search in DiVA

Show all publications